Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura

被引：1
|
作者：
Goshua, George
Sinha, Pranay
Hendrickson, Jeanne E.
Tormey, Christopher A.
Bendapudi, Pavan
Lee, Alfred Ian
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura
    Sargentini-Maier, Maria Laura
    De Decker, Philip
    Tersteeg, Claudia
    Canvin, Jan
    Callewaert, Filip
    De Winter, Hilde
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (06) : 537 - 545
  • [32] Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
    Agosti, Pasquale
    Leo, Pasqualina De
    Capecchi, Marco
    Ferrari, Barbara
    Mancini, Ilaria
    Gattillo, Salvatore
    Trisolini, Silvia Maria
    Rinaldi, Erminia
    Podda, Gian Marco
    Prezioso, Lucia
    Salutari, Prassede
    Facchini, Luca
    Caramazza, Domenica
    Tolomelli, Giulia
    Artoni, Andrea
    Peyvandi, Flora
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (06)
  • [33] Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective
    Pollissard, Laurence
    Leinwand, Brian, I
    Fournier, Marie
    Pham, Huy P.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1178 - 1184
  • [34] Caplacizumab for acquired thrombotic thrombocytopenic purpura - results of the phase 3 HERCULES study
    Scully, M.
    Cataland, S.
    Peyvandi, F.
    Coppo, P.
    Knoebl, P.
    Hovinga, J. A. Kremer
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    de Winter, H.
    Zeldin, R. K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 18 - 18
  • [35] CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): TECHNOLOGY QUALIFICATION IN COLOMBIA
    Soto, J.
    Gomez, L. M.
    Lasalvia, P.
    Castellanos, C.
    Casallas, C.
    Londono, S.
    VALUE IN HEALTH, 2023, 26 (06) : S274 - S274
  • [36] HEALTHCARE COSTS AVOIDED IN THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA WITH CAPLACIZUMAB IN COLOMBIA
    Londono, S.
    Gil-Rojas, Y.
    Lasalvia, P.
    VALUE IN HEALTH, 2023, 26 (06) : S69 - S69
  • [37] Patient with Refractory Acquired Thrombotic Thrombocytopenic Purpura Treated with a Novel Agent Caplacizumab
    Sharma, Pranav
    Lebowitz, Jonathan
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 141 - 141
  • [38] Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
    Logothetis, Constantine N.
    Patel, Ankita
    Eatrides, Jennifer
    Jaglal, Michael
    Haider, Mintallah
    Visweshwar, Nathan
    Laber, Damian A.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (15)
  • [39] Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis
    Peyvandi, Flora
    Cataland, Spero
    Scully, Marie
    Coppo, Paul
    Knoebl, Paul
    Hovinga, Johanna A. Kremer
    Metjian, Ara
    de la Rubia, Javier
    Pavenski, Katerina
    Edou, Jessica Minkue Mi
    De Winter, Hilde
    Callewaert, Filip
    BLOOD ADVANCES, 2021, 5 (08) : 2137 - 2141
  • [40] Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura
    Reti, Marienn
    Sinkovits, Gyorgy
    Varkonyi, Andrea
    Kiraly, Agnes
    Farkas, Zita
    Bogsch, Luca
    Icleanu, Andreea-Adela
    Masszi, Tamas
    Valyi-Nagy, Istvan
    Prohaszka, Zoltan
    Remenyi, Peter Pal
    BLOOD, 2023, 142
12345